SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron.
Viruses
; 14(1)2022 01 02.
Artigo
em Inglês
| MEDLINE | ID: covidwho-1614001
ABSTRACT
Omicron, the most recent SARS-CoV-2 variant of concern (VOC), harbours multiple mutations in the spike protein that were not observed in previous VOCs. Initial studies suggest Omicron to substantially reduce the neutralizing capability of antibodies induced from vaccines and previous infection. However, its effect on T cell responses remains to be determined. Here, we assess the effect of Omicron mutations on known T cell epitopes and report data suggesting T cell responses to remain broadly robust against this new variant.
Palavras-chave
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T
/
Vacinas contra COVID-19
/
SARS-CoV-2
Tópicos:
Vacinas
/
Variantes
Limite:
Humanos
Idioma:
Inglês
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
V14010079
Similares
MEDLINE
...
LILACS
LIS